Bleeding Risk, MI
Bleeding Risk, MI estimates the likelihood of major bleeding versus recurrent myocardial infarction to guide antithrombotic intensity in post‑MI patients.
使用適応
Used to stratify major bleeding and perioperative MI risk in adults undergoing non‑cardiac surgery when results could change perioperative management (eg, antiplatelet/anticoagulant interruption, need for cardiac optimization). Provides individualized estimates of bleeding vs thrombotic events to balance therapy (AHA/ACC 2024 perioperative guideline 1). Useful for shared decision‑making, tailoring antithrombotic strategies, and identifying patients requiring enhanced monitoring.
洞察と注意事項
Bleeding risk rises with perioperative aspirin or unnecessary anticoagulant bridging; POISE‑2 showed no MI reduction but 23% more major bleeding 1. Correct anemia pre‑op because low hemoglobin increases MI and mortality. MI risk increases with poor functional capacity, high‑risk surgery, prior CAD, and perioperative hypotension or anemia. Perioperative MI is often type 2; symptoms may be absent, so troponin surveillance is key. Balancing antithrombotic therapy against bleeding risk is essential.